The Recall Desk
LowFDA (Drugs)·D-1099-2018·Announced 2018-08-22

FDA Recalls Contrave Tablets Due to Punctured Bottle Complaints

Orexigen Therapeutics is recalling 95,296 bottles of Contrave extended-release tablets due to customer complaints of punctures in the bottles.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences. The issue is a packaging defect (punctures) without reported injuries or illnesses.

Plain-English summary

Orexigen Therapeutics, Inc. is recalling 95,296 bottles of Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, 8 mg/90 mg, 120-count. The recall is being conducted due to customer complaints regarding punctures in the bottles.

The affected product is distributed nationwide in the USA. The specific lots involved are ZCXM, ZCXN, ZCXP, ZCXS, ZCXT, and ZCXV, with expiration dates ranging from November 2020. The product is a prescription-only medication.

Consumers with this product should contact their healthcare provider or the recalling firm for further instructions.

The recalled product

Product
CONTRAVE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)
Brand
CONTRAVE
Affected units
95,296

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (12)

  • Lot #: ZCXM
  • Exp 01NOV2020
  • ZCXN
  • Exp 02NOV2020
  • ZCXP
  • Exp 09NOV2020
  • ZCXS
  • 10NOV2020
  • ZCXT
  • Exp 13NOV2020
  • and ZCXV
  • Exp 17NOV2020

UPCs (1)

  • 0351267890997

Distribution

Distributed nationwide across the United States.

Same brand · CONTRAVE